Topoisomerase II alpha Blocking Peptide is synthetically produced from the 1220-1270 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide taken within amino acid region 1220-1270 on human DNA topoisomerase (ATP-hydrolysing) protein.
Immunogen Region
1220-1270
Additional Info
Tissue Specificity
Expressed in the tonsil, spleen, lymph node, thymus, skin, pancreas, testis, colon, kidney, liver, brain and lung. Also found in high-grade lymphomas, squamous cell lung tumors and seminomas.
Post Translational Modifications
Phosphorylation has no effect on catalytic activity. However, phosphorylation at Ser-1106 by CSNK1D/CK1 promotes DNA cleavable complex formation. (Microbial infection) Deubiquitinated by Epstein-Barr virus BPLF1.leading to stabilized SUMOylated TOP2A trapped in cleavage complexes, which halts the DNA damage response to TOP2A-induced double-strand DNA breaks. SUMOylated.
Function
Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand. May play a role in regulating the period length of BMAL1 transcriptional oscillation.
Peptide Name
Dna Topoisomerase 2-AlphaDna Topoisomerase Ii - Alpha Isozyme
